BioStem Technologies, Inc., a regenerative medicine company specializing in perinatal tissue allograft products, has filed its audited consolidated financial statements for the fiscal years ended December 31, 2024 and 2025. The documents are available for review on the OTC Markets website at https://www.otcmarkets.com. This publication represents a significant milestone as the company progresses toward an uplisting to the Nasdaq stock exchange.
Jason Matuszewski, Chairman and CEO of BioStem Technologies, stated that the achievement, alongside recent appointments of a new CFO, auditor, and audit committee chair, underscores the company's efforts to establish robust financial reporting processes. He emphasized that listing on Nasdaq remains a top priority, which would increase visibility, improve stock liquidity, provide a more precise market valuation, and enhance the ability to attract top talent. The company's focus on advancing corporate initiatives includes this strategic move to strengthen its market position.
BioStem Technologies leverages proprietary processing technologies such as BioRetain®, CryoTek®, and SteriTek® to optimize the preservation of natural tissue properties for clinical use. Its allografts are utilized by clinicians across various specialties, supported by a quality management system accredited by the American Association of Tissue Banks and compliant with current Good Tissue Practices and Good Manufacturing Processes. The company's product portfolio includes brands like Neox®, Clarix®, VENDAJE®, and American Amnion™, with more information available at https://biostemtechnologies.com.
The importance of this development lies in its implications for the regenerative medicine industry and investors. An uplist to Nasdaq could enhance BioStem's credibility and access to capital, potentially accelerating innovation and market penetration of its allograft solutions. For the medical community, this may translate into broader availability of advanced treatments for tissue repair and regeneration. However, forward-looking statements in the press release caution that actual outcomes may differ due to risks such as competition, technological changes, reimbursement challenges, and economic factors, highlighting the need for cautious optimism in assessing the company's future trajectory.
